- Home
- SONN vs INM Comparison
SONN vs INM Comparison
Compare SONN & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- INM
- Stock Information
- Founded
- SONN N/A
- INM 1981
- Country
- SONN United States
- INM Canada
- Employees
- SONN N/A
- INM N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- INM Health Care
- Exchange
- SONN Nasdaq
- INM Nasdaq
- Market Cap
- SONN 3.8M
- INM 3.2M
- IPO Year
- SONN N/A
- INM N/A
- Fundamental
- Price
- SONN $1.11
- INM $2.45
- Analyst Decision
- SONN Strong Buy
- INM
- Analyst Count
- SONN 1
- INM 0
- Target Price
- SONN $20.00
- INM N/A
- AVG Volume (30 Days)
- SONN 46.3K
- INM 3.9M
- Earning Date
- SONN 08-13-2025
- INM 05-12-2025
- Dividend Yield
- SONN N/A
- INM N/A
- EPS Growth
- SONN N/A
- INM N/A
- EPS
- SONN N/A
- INM N/A
- Revenue
- SONN $1,000,000.00
- INM $4,920,990.00
- Revenue This Year
- SONN $5,376.22
- INM N/A
- Revenue Next Year
- SONN N/A
- INM N/A
- P/E Ratio
- SONN N/A
- INM N/A
- Revenue Growth
- SONN 978.39
- INM N/A
- 52 Week Low
- SONN $1.08
- INM $1.72
- 52 Week High
- SONN $10.02
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- SONN 38.81
- INM 44.00
- Support Level
- SONN $1.11
- INM $2.30
- Resistance Level
- SONN $1.25
- INM $2.53
- Average True Range (ATR)
- SONN 0.06
- INM 0.30
- MACD
- SONN 0.00
- INM -0.05
- Stochastic Oscillator
- SONN 0.00
- INM 10.79
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.